{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:32:42Z","timestamp":1788805962567,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK 20191321"],"award-info":[{"award-number":["BK 20191321"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20220087"],"award-info":[{"award-number":["BK20220087"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872799"],"award-info":[{"award-number":["81872799"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473789"],"award-info":[{"award-number":["82473789"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173673"],"award-info":[{"award-number":["82173673"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930100"],"award-info":[{"award-number":["81930100"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2632024TD10"],"award-info":[{"award-number":["2632024TD10"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bmc.2024.117902","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T13:01:42Z","timestamp":1725022902000},"page":"117902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Recent advances in the design of small molecular drugs with acrylamides covalent warheads"],"prefix":"10.1016","volume":"112","author":[{"given":"Luxia","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-5504","authenticated-orcid":false,"given":"Xiaoke","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117902_b0005","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1002\/anie.201707875","article-title":"The cysteinome of protein kinases as a target in drug development","volume":"57","author":"Chaikuad","year":"2018","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2024.117902_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103799","article-title":"The expanding repertoire of covalent warheads for drug discovery","volume":"28","author":"Mehta","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2024.117902_b0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cmdc.201500469","article-title":"Designing irreversible inhibitors\u2014worth the effort?","volume":"11","author":"Gonz\u00e1lez-Bello","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117902_b0020","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1021\/acs.jmedchem.1c02134","article-title":"The ascension of targeted covalent inhibitors","volume":"65","author":"Singh","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0025","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2024.117902_b0030","doi-asserted-by":"crossref","first-page":"53508","DOI":"10.18632\/oncotarget.18588","article-title":"Structural basis of mutant-selectivity and drug-resistance related to CO-1686","volume":"8","author":"Yan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2024.117902_b0035","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1039\/D0MD00154F","article-title":"Covalent inhibitors: a rational approach to drug discovery","volume":"11","author":"Sutanto","year":"2020","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0040","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117902_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27227728","article-title":"Covalent warheads targeting cysteine residue: the promising approach in drug development","volume":"27","author":"Huang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2024.117902_b0050","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0055","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cmdc.201900107","article-title":"Covalent inhibition in drug discovery","volume":"14","author":"Ghosh","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117902_b0060","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1021\/jp8111556","article-title":"Consistent van der Waals Radii for the whole main group","volume":"113","author":"Mantina","year":"2009","journal-title":"J Phys Chem C"},{"key":"10.1016\/j.bmc.2024.117902_b0065","series-title":"The nature of the chemical bond","author":"Pauling","year":"1960"},{"key":"10.1016\/j.bmc.2024.117902_b0070","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1021\/ja00207a003","article-title":"Electronegativity is the average one-electron energy of the valence-shell electrons in ground-state free atoms","volume":"111","author":"Allen","year":"1989","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117902_b0075","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1039\/C6MD00017G","article-title":"Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-\u03b1-acetyl-l-lysine as an amine nucleophile","volume":"7","author":"Dahal","year":"2016","journal-title":"MedChemComm."},{"key":"10.1016\/j.bmc.2024.117902_b0080","doi-asserted-by":"crossref","first-page":"11602","DOI":"10.1021\/acs.jmedchem.0c00749","article-title":"Systematic study of the glutathione reactivity of N-phenylacrylamides: 2. Effects of acrylamide substitution","volume":"63","author":"Birkholz","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0085","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0076-6879(91)02027-7","article-title":"Hydrophobic parameter: Measurement and calculation","volume":"202","author":"Leo","year":"1991","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.bmc.2024.117902_b0090","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/jm960789h","article-title":"Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding","volume":"40","author":"Palmer","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0095","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1124\/dmd.122.000895","article-title":"Metabolic activation of the acrylamide michael acceptor warhead in futibatinib to an epoxide intermediate engenders covalent inactivation of CYP3A","volume":"50","author":"Tang","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2024.117902_b0100","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1021\/acs.jmedchem.5b01018","article-title":"Systematic study of the glutathione (GSH) reactivity of N-arylacrylamides: 1. Effects of aryl substitution","volume":"58","author":"Cee","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0105","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1021\/acs.jcim.7b00553","article-title":"Expanding the armory: predicting and tuning covalent warhead reactivity","volume":"57","author":"Lonsdale","year":"2017","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2024.117902_b0110","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0115","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/jm5014659","article-title":"A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles","volume":"57","author":"Xia","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14756360701425014","article-title":"The role of fluorine in medicinal chemistry","volume":"22","author":"Shah","year":"2007","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0125","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1021\/ja012633z","article-title":"Stereoelectronic effects and general trends in hyperconjugative acceptor ability of \u03c3 bonds","volume":"124","author":"Alabugin","year":"2002","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117902_b0130","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/acsmedchemlett.1c00052","article-title":"Investigation of covalent warheads in the design of 2-aminopyrimidine-based FGFR4 inhibitors","volume":"12","author":"Deng","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117902_b0135","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2024.117902_b0145","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1021\/acs.jmedchem.8b00571","article-title":"Development, optimization, and structure-activity relationships of covalent-reversible JAK3 inhibitors based on a tricyclic imidazo[5,4-d]pyrrolo[2,3-b]pyridine scaffold","volume":"61","author":"Forster","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cbpa.2016.08.011","article-title":"Targeting biomolecules with reversible covalent chemistry","volume":"34","author":"Bandyopadhyay","year":"2016","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.bmc.2024.117902_b0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tibtech.2011.12.002","article-title":"Exploiting cell surface thiols to enhance cellular uptake","volume":"30","author":"Torres","year":"2012","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.bmc.2024.117902_b0160","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1021\/jm00044a013","article-title":"Stereospecific synthesis of peptidyl.alpha.-keto amides as inhibitors of calpain","volume":"37","author":"Scott","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0165","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1021\/acs.jmedchem.2c01005","article-title":"Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure-activity relationship insights and evolution perspectives","volume":"65","author":"La MonicaAlessia","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0170","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1021\/acs.jmedchem.0c01808","article-title":"The alpha keto amide moiety as a privileged motif in medicinal chemistry: current insights and emerging opportunities","volume":"64","author":"Robello","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1006384521198","article-title":"Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results","volume":"17","author":"Huang","year":"1999","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bmc.2024.117902_b0180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdf039","article-title":"Very young women (< 35 years) with operable breast cancer: features of disease at presentation","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmc.2024.117902_b0185","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejca.2004.10.014","article-title":"Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy","volume":"41","author":"Hitt","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2024.117902_b0190","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1126\/science.8066447","article-title":"A specific inhibitor of the epidermal growth factor receptor tyrosine kinase","volume":"265","author":"Fry","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.bmc.2024.117902_b0195","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00873135","article-title":"Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice","volume":"13","author":"Kunkel","year":"1995","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bmc.2024.117902_b0200","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1073\/pnas.95.20.12022","article-title":"Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor","volume":"95","author":"Fry","year":"1998","journal-title":"PNAS"},{"key":"10.1016\/j.bmc.2024.117902_b0205","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0006-2952(98)00356-6","article-title":"Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)","volume":"57","author":"Discafani","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2024.117902_b0210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1758834016687262","article-title":"Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications","volume":"9","author":"Juan","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bmc.2024.117902_b0215","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2024.117902_b0220","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1021\/acs.jmedchem.6b00883","article-title":"Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido [3, 4-d] pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family","volume":"59","author":"Smaill","year":"2016","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.bmc.2024.117902_b0225","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/acs.jmedchem.4c01122","article-title":"An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013\u20132023)","volume":"67","author":"Marshall","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0230","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2024.117902_b0235","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-018-1028-x","article-title":"Dacomitinib: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2024.117902_b0240","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: first global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2024.117902_b0245","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ctrv.2012.04.008","article-title":"Current approaches and future directions in the treatment of HER2-positive breast cancer","volume":"39","author":"Hurvitz","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bmc.2024.117902_b0250","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1021\/acs.jmedchem.1c00710","article-title":"Discovery of SPH5030, a selective, potent, and irreversible tyrosine kinase inhibitor for HER2-amplified and HER2-mutant cancer treatment","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0255","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.4918.4918","article-title":"B cell receptor (BCR) signal pathways confer microenvironment-mediated drug resistance and are promising therapeutic targets for B cell lymphomas","volume":"120","author":"Tao","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2024.117902_b0260","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41577-024-00996-9","article-title":"The conneXion between sex and immune responses","volume":"24","author":"Forsyth","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmc.2024.117902_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113329","article-title":"Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): current development","volume":"217","author":"Liu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0270","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117902_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127862","article-title":"Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): kinase inhibitors","volume":"38","author":"Zheng","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117902_b0280","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","article-title":"Ibrutinib: first global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2024.117902_b0285","first-page":"1491","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC: Clin Electrophysiol"},{"key":"10.1016\/j.bmc.2024.117902_b0290","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.bmc.2024.117902_b0295","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1161\/CIRCULATIONAHA.120.052047","article-title":"Cardio-oncology: a win-win situation: how solving the mystery of an ibrutinib off-target effect reveals new insights into atrial fibrillation mechanisms","volume":"142","author":"Awan","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.bmc.2024.117902_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-3-4","article-title":"Ibrutinib for B cell malignancies","volume":"3","author":"Novero","year":"2014","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.bmc.2024.117902_b0305","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/sji.12333","article-title":"Targets for ibrutinib beyond B cell malignancies","volume":"82","author":"Bergl\u00f6f","year":"2015","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.bmc.2024.117902_b0310","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of reversible covalent Bruton\u2019s tyrosine kinase inhibitors PRN473 and PRN1008 (Rilzabrutinib)","volume":"65","author":"Owens","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0315","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/bcp.13351","article-title":"A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2024.117902_b0320","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117902_b0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2024.117902_b0330","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117902_b0335","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2024.117902_b0340","doi-asserted-by":"crossref","unstructured":"Race for undruggable KRAS speeds up. Nat Biotechnol 2019;37(11):1247. doi: 10.1038\/s41587-019-0312-y.","DOI":"10.1038\/s41587-019-0312-y"},{"key":"10.1016\/j.bmc.2024.117902_b0345","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117902_b0350","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.chembiol.2017.06.017","article-title":"Potent and selective covalent quinazoline inhibitors of KRAS G12C","volume":"24","author":"Zeng","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2024.117902_b0355","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/acsmedchemlett.8b00382","article-title":"Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity","volume":"9","author":"Fell","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117902_b0360","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1021\/acsmedchemlett.9b00258","article-title":"Discovery of N-(1-acryloylazetidin-3-yl)-2-(1H-indol-1-yl) acetamides as covalent inhibitors of KRASG12C","volume":"10","author":"Shin","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117902_b0365","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0370","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2024.117902_b0375","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bmc.2024.117902_b0380","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117902_b0385","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2024.117902_b0390","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bmc.2024.117902_b0395","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cmdc.201300520","article-title":"Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes","volume":"9","author":"Gehringer","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.117902_b0400","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1074\/jbc.M114.595181","article-title":"Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol","volume":"290","author":"Goedken","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0405","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1021\/acs.jmedchem.5b00710","article-title":"Development of selective covalent Janus kinase 3 inhibitors","volume":"58","author":"Tan","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0410","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmc.2024.117902_b0415","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0420","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1021\/acs.jmedchem.8b01823","article-title":"Discovery of an orally available Janus kinase 3 selective covalent inhibitor","volume":"62","author":"Shi","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0425","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.chembiol.2016.10.008","article-title":"Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket","volume":"23","author":"Forster","year":"2016","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2024.117902_b0430","doi-asserted-by":"crossref","first-page":"21937","DOI":"10.1021\/jacs.3c06622","article-title":"Chemical specification of E3 ubiquitin ligase engagement by cysteine-reactive chemistry","volume":"145","author":"Sarott","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117902_b0435","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.chembiol.2021.04.007","article-title":"Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation","volume":"28","author":"Kannt","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2024.117902_b0440","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17997-6","article-title":"Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry","volume":"11","author":"Guo","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117902_b0445","doi-asserted-by":"crossref","first-page":"11734","DOI":"10.1021\/jacs.9b13907","article-title":"Efficient targeted degradation via reversible and irreversible covalent PROTACs","volume":"142","author":"Gabizon","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117902_b0450","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117902_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(03)00028-7","article-title":"Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase","volume":"58","author":"De Francesco","year":"2003","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2024.117902_b0460","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.50.3.1013-1020.2006","article-title":"SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells","volume":"50","author":"Malcolm","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117902_b0465","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2024.117902_b0470","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2024.117902_b0475","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2024.117902_b0480","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1021\/acs.jmedchem.8b00260","article-title":"Synthetic approaches to new drugs approved during 2016","volume":"61","author":"Flick","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117902_b0485","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1021\/acsptsci.2c00065","article-title":"The remarkable selectivity of nirmatrelvir","volume":"5","author":"Duveau","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.bmc.2024.117902_b0490","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmc.2024.117902_b0495","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L.","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmc.2024.117902_b0500","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1080\/07391102.2020.1831610","article-title":"Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2","volume":"40","author":"Paul","year":"2022","journal-title":"J Biomol Struct Dyn"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962400316X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962400316X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:31:34Z","timestamp":1778574694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962400316X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":100,"alternative-id":["S096808962400316X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117902","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the design of small molecular drugs with acrylamides covalent warheads","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117902"}}